Abstract | Lipodystrophy is a medical condition characterized by complete or partial loss of adipose tissue. Not infrequently, lipodystrophy occurs in combination with pathological accumulation of adipose tissue at distinct anatomical sites. Patients with lipodystrophy exhibit numerous metabolic complications, which indicate the importance of adipose tissue as an active endocrine organ. Not only the total amount but also the appropriate distribution of adipose tissue depots contribute to the metabolic state. Genetic and molecular research has improved our understanding of the mechanisms underlying lipodystrophy. Circulating levels of hormones secreted by the adipose tissue, such as leptin and adiponectin, are greatly reduced in distinct subpopulations of patients with lipodystrophy. This finding rationalizes the use of these adipokines or of agents that increase their circulating levels, such as peroxisome proliferator-activated receptor γ (PPARγ) agonists, for therapeutic purposes. Other novel therapeutic approaches, including the use of growth hormone and growth-hormone-releasing factors, are also being studied as potential additions to the therapeutic armamentarium. New insights gained from research and clinical trials could potentially revolutionize the management of this difficult-to-treat condition.
Introduction
lipodystrophy is an umbrella term used to describe a diverse group of metabolic disorders characterized by either complete or partial loss of adipose tissue (lipo atrophy) that can occur in conjunction with the patho logical accumulation of adipose tissue (lipo hypertrophy) in other distinct regions of the body. metabolic abnormali ties, such as insulin resistance, diabetes mellitus, hypertriglyceridemia and hepatic steatosis, are frequently observed in patients with lipo dystrophy, and the severity of such comorbidities typi cally correlates with the degree of adipose tissue loss. other common complications include acanthosis nig ricans, polycystic ovary syndrome, hypertension and proteinuric kidney disease. 1 lipodystrophy can be inherited or acquired, although inherited lipodystrophic syndromes are exceedingly rare. currently, the most prevalent type of lipo dystrophy is an acquired form that occurs in hivinfected indivi duals treated with highly active antiretroviral therapy (haart). up to 40-70% of patients on haart are reported to have hivassociated lipodystrophy sy ndrome (hals). 2, 3 the clinical diagnosis of lipodystrophy is made on the basis of findings from a physical examination. the degree of adipose tissue loss or redistribution is not necessary for the diagnosis of lipodystrophy but can be measured in clinical settings; however, this analysis is more frequently performed for research purposes. adipose tissue loss and/or redistribution can be estimated with anthropo metry. although measurements of skin folds, hip, waist and limb circumferences are costeffective and practi cal, and thus frequently used, more accurate methods are available. Dualenergy xray absorptio metry (DXa), mri and ct offer superior objectivity and precision. 4 these techniques, however, are not used in everyday clini cal practice owing to high costs and lack of avail ability. ultrasonography is an emerging alternate quantitative tool that is accurate as well as comparatively affordable and accessible. 5 research efforts have improved our understanding of the molecular mechanisms underlying lipodystrophy and are thus providing new treatment approaches. this review describes the various types of lipodystrophy syn dromes known to date, as well as mechanisms responsible for concomitant metabolic abnormalities, and provides a perspective on current treatment options and novel therapeutic approaches, with a focus on the adipokines leptin and adiponectin.
Types of lipodystrophy
lipodystrophies are categorized according to both the etiology (congenital or acquired) and the pattern of adipose tissue loss, which can be either generalized (affecting the whole body) or partial (affecting specific body regions). the more common types of lipodystrophy are discussed as follows, whereas information on rarer types of lipodystrophy can be found in table 1.
generalized lipodystrophy
Congenital generalized lipodystrophy congenital generalized lipodystrophy (cGl), or Berardinelliseip syndrome, is a rare autosomal reces sive disorder that is characterized by a neartotal lack of body adipose tissue. approximately 250 cases of cGl have been described in the literature. this syndrome is ubiquitous to all geographic regions, 6 with the highest frequency reported in Brazil. 7, 8 cGl occurs most frequently in instances of parental consanguinity and is diagnosed soon after birth. Despite voracious appetites and accelerated linear growth rates, children with cGl demonstrate markedly reduced subcutaneous adiposity. cGl is also associated with diabetes mellitus, hypertriglyceridemia, hepatic steato sis, cirrhosis, acromegaloid features and acanthosis nigricans. cardiomyopathy, mild mental retardation, advanced bone age, 6 cervical spine instability and mus cular weakness have also been reported. 9 reproductive function is severely impaired in women, but usually unaffected in men. Females commonly present with clitoromegaly, hir sutism, amenorrhea or irregular men strual cycles and ovarian cysts. 6 Finally, levels of leptin and adiponectin, hormones produced in adipose tissue, are low in both sexes. 10 cGl is classified as type 1 or type 2, depending on the genetic mutation and the associated phenotype. cGl1 is associated with a mutation of the AGPAT2 gene on chromo some 9q34. the aGPat2 protein is an enzyme that catalyzes the formation of phosphatidic acid, an intracellular signaling molecule that is critical for normal adipocyte function and plays a part in triacyl glycerol synthesis in adipose tissue.
11 only metabolically impor tant adipose tissue (that is, sub cutaneous, bone marrow, intraabdominal, intermuscular and intra thoracic depots) and not mechanically important adipose tissue (that is, in the scalp, surrounding the joints and in the soles, the palms and the orbital region) is markedly reduced in patients with cGl1. 12 cGl2 is associated with mutations of the BSCL2 gene on chromosome 11q13. 13 BSCL2 encodes the protein seipin, a molecule hypothesized to influence adipocyte additionally, several other gene mutations have been associated with cGl, two of which result in primary or secondary caveolin deficiency. caveolins are critical elements of the caveolae-invaginations of the plasma membrane involved in signal transduction and cel lular transport. 16 mutations in CAV1, 17 a gene which encodes the protein caveolin 1, and PTRF, a gene that encodes a caveolarassociated protein (polymerase i and transcript release factor), 18 have both been associated with a lipodystrophic phenotype. in addition to lipo dystrophy, patients with PTRF mutations also suffer from muscular dystrophy. 18 Acquired generalized lipodystrophy acquired generalized lipodystrophy, or lawrence-seip syndrome, shares many features with cGl, includ ing severely reduced subcutaneous adiposity, insulin resistance or diabetes mellitus, acanthosis nigricans, hypertriglyceridemia, hepatic steatosis, hypoleptinemia and hypoadiponectinemia. 10, 19 in addition to reduced sub cutaneous adiposity, adipose tissue is reduced in the palms, soles and intraabdominal area. acquired generaliz ed lipodystrophy is usually diagnosed during childhood or adolescence and affects threefold more women than men.
approximately 25% of cases are caused by pannicu litis (an inflammatory reaction of the subcutaneous adipose tissue), 25% by autoimmune disease and 50% are of idiopathic origin. 19 autoimmune disorders that have been associated with acquired generalized lipo dystrophy include juvenileonset dermatomyositis, rheumatoid arthritis, systemic lupus erythematosus and sjögren syndrome. 20 
Partial lipodystrophy
Inherited partial lipodystrophy many types of inherited partial lipodystrophy exist, most of which are extremely rare. although a genetic locus has not yet been identified for familial partial lipo dystrophy type 1 (FPlD1), numerous genetic mutations have been implicated in other types of inherited partial lipo dystrophy, including the LMNA gene in FPlD2 21 and the gene that encodes peroxisome proliferator activated receptor γ (PPARγ) in FPlD3. 22 mutations in AKT2 23, 24 and CIDEC 25 have also been reported in a small number of patients with inherited partial lipo dystrophy. Patients with partial lipodystrophy associ ated with mandibuloacr al dysplasia have mutations in the LMNA gene (type a), 26 which are distinct from those observed with FPlD2, or the ZMPSTE24 gene (type B). 27 these rare forms of inherited partial lipo dystrophy are described in table 1.
the most prevalent form of inherited partial lipo dystrophy is FPlD2, also known as Dunnigantype familial partial lipodystrophy. FPlD2 is inherited in an autosomal dominant manner and is caused by mutations in the LMNA gene located on chromosome 1q21-22. 21 reviewS the LMNA gene encodes the nuclear envelope proteins lamin a and c, which are structural proteins that mediate the integrity and assembly of the nucleus. lamin a has also been associated with adipocyte differentiation, insulin signaling and PParγ signaling.
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FPlD2 has been reported in over 200 patients, with an estimated prevalence of one in 15 million individuals. FPlD2 develops during puberty and results in gradual atrophy of sub cutaneous adipose tissue in the extremities, followed by loss of adiposity in the anterior abdomen and chest, which gives the appearance of increased mus cularity.
Patients also have accumulation of adipose tissue in the face, neck and intraabdominal areas, causing a cushingoid appearance. 28 metabolic complications, such as diabetes mellitus, hypertriglyceridemia, low hDl cholesterol levels and high fasting concentrations of serum free fatty acids (FFas), are prevalent in patients with FPlD2 and affect women more severely than men. 29 additionally, women with FPlD2 have an increased risk of many reproduc tive abnormalities, including polycystic ovary syndrome, infertility and gestational diabetes mellitus. 30 cardiac and skeletal muscle abnormalities are common; muscle hyper trophy, multiple nerve entrapment syndromes and severe myalgias have been reported in a number of patients with FPlD2. 31 in contrast to other types of lipodystrophy, patients with FPlD2 have only modestly reduced leptin and adiponectin levels, 10 perhaps because lipoatrophy is less extensive in these individuals.
Acquired partial lipodystrophy
approximately 250 cases of acquired partial lipo dystrophy, or Barraquer-simons syndrome, have been described. the majority of patients with this type of lipodystrophy are of european descent. the condi tion affects four to eight times more women than men and typically has a childhood or adolescent onset. a Anghel et al. 84 Monajemi et al. 197 Rosen et al. 33 a high association between acquired partial lipodystrophy and membrano proliferative glomerulonephritis-a condition charac terized by mesangial cell proliferation and irregular thickening of the glomerular capillary wall that can lead to renal failure-has also been found. Patients with both acquired partial lipodystrophy and membrano proliferative glomerulo nephritis tend to have low serum levels of complement c3 and exhibit the polyclonal immuno globulin auto antibody c3 nephritic factor in the serum. c3 nephritic factor has been hypothesized to induce the lysis of adipocytes that express complement factor D (a serine protease also referred to as adipsin). Differential expression of complement factor D by various tissues in the body dictates the cephalocaudal pattern of adipose tissue loss characteristic of acquired partial lipo dystrophy.
33,34 however, this type of lipo dystrophy may also be caused by mutations in the LMNB2 gene, which encodes lamin B, as hegele et al. 35 found a rare mutation in this gene to be more frequent in patients with acquired partial lipodystrophy than control individuals.
HAART-associated lipodystrophy syndrome although haart has greatly reduced mortality rates in patients with hiv or aiDs, the associated lipodystrophy syndrome hals and its metabolic complications have become a substantial concern. hals is considered to be primarily an adverse effect of haart and is distinct from hivrelated wasting, which is caused by either hiv infection itself or opportunistic infections and cancers. additionally, hivrelated wasting involves not only adipose tissue but also other tissues, such as muscle. the pattern of adipose tissue loss is also different.
Patients with hals can experience lipoatrophy, lipo hypertrophy or a combination of both. 36 wasting of the face, arms, legs and buttocks is common 36 and can occur along with accumulation of adipose tissue in the abdomen and dorsocervical area (Figure 1 ), although the latter is less frequent.
37 risk factors for hals include age, greater severity of hivinfection, increased viral load, low count of cD4positive t lymphocytes and coinfec tion with hepatitis c virus.
38,39 hals increases the risk of insulin resistance, diabetes mellitus, dyslipidemia, and cardiovascular disease. 40 although antiretroviral regimens used to treat hals have been implicated in the etiology of the condition, the mechanisms by which these therapies contribute to lipodystrophy are incompletely understood. nucleoside reverse transcriptase inhibitors (nrtis), such as stavu dine or zidovudine, may contribute to hals via several mechanisms, including mitochondrial toxicity, 41 which is characterized by abnormal changes in mito chondrial proliferation, morphology and Dna content. 41, 42 Protease inhibitors, such as indinavir and saquinavir, have been shown to disrupt adipocyte differentiation via the down regulation of several adipogenic transcription factors, including PParγ and c/eBPα. 43 additional metabolic disturbances that occur in hivinfected individuals who take protease inhibitors include the generation of reac tive oxygen species, 44,45 increased macrophage recruit ment, 44 inhibition of Glut4mediated glucose transport, impairment of insulin signaling, impairment of leptin and/or adiponectin secretion and enhanced produc tion of cytokines, such as interleukin 6 (il6) and tumor necrosis factor (tnF).
2 in contrast to protease inhibitors and nrtis, evidence which suggests that nonnucleoside reverse transcriptase inhibitors (nnrtis), such as nevirapine or efavirenz, cause lipodystrophy and other metabolic changes is less direct. several trials have reported that lipodystrophy is rare among hivinfected individuals who receive nnrtis, and the risk of developing lipodystrophy and other metabolic complications may be more dependent on drugs used in combination with these agents. 46, 47 however, some conflicting evidence suggests that the nnrti efavirenz, when combined with either stavu dine or zidovudine, may result in greater adipose tissue loss than a combination of two nrtis with the protease inhibitors lopinavir plus ritonavir. 48 lipoatrophy was lowest with the nrtisparing regimen of lopinavir plus ritonavir and efavirenz, but this combination resulted in higher cholesterol levels than therapy with an nrti. 48 additionally, in vitro data has shown that efavirenz may prevent the accumulation of lipids in preadipocytes, 49 reduce lipid content in mature adipocytes, 49 inhibit gene expression of SREBP1c (sterol response element binding protein 1c), 49 inhibit mitochondrial activity, 50 increase the production of reactive oxygen species 50 and increase intracellular lipids in hepatic cells. 50 Further research is needed to determine if and how specific antiretroviral regimens contribute to lipodystrophy and its associated metabolic abnormalities.
Genetic background may predispose patients on haart to develop pathological distribution of adipose tissue and other metabolic abnormalities. a single nucleo tide polymorphism in the resistin gene (RETN) has been associated with an elevated risk of developing high lipid levels, insulin resistance and loss of adipose tissue in limbs in patients who receive haart. 51 other studies have implicated a polymorphism in the tnF pro moter region with a more rapid onset of hals, 52 but this finding needs to be confirmed by further studies. viral proteins and mechanisms related to hiv1 infection have been suggested to influence adipose tissue distribution directly. hiv1 viral protein r has been found to act as a corepressor of PParγmediated gene transcription in vitro, which may inhibit adipocyte differentiation in vivo. Furthermore, hiv1 infection per se is thought to lead to a proinflammatory environment, which could contribute to lipodystrophy and related metabolic dis turbances.
37 hals has been associated with increased expression of proinflammatory cyto kines, including tnF, ccchemokine ligand 2 (also known as mcP1), and macrophage markers, including cD68, integrin αm, emr1 and aDam8, in adipose tissue. 55 Biopsies of subcutaneous adipose tissue have revealed increases in tnF secretion, the number of macrophages and mito chondrial expression of il1β in patients with hals compared with hivinfected patients without lipoatrophy. 56,57 in addition, hals is associated with increased systemic cytokine activity, including ele vated levels of il6 and soluble tnF receptors i and ii.
57 inflammation is thought to contribute to insulin resistance via impaired adipocyte metabolism and lipo lysis.
58 in addition, tnF mediates insulin resistance via a reduction in insulin receptor kinase activity, down regulation of insulin receptor substrate 1 (irs1) and Glut4 phosphorylation and acti vity and induction of lipolysis.
2 chronic elevation of il6 promotes hepatic gluconeogenesis and induces hepatic triglyceride secre tion, possibly through impairing insulin signaling via irs1 and phosphatidylinositol 3kinase (Pi3K).
2 in mice, mcP1 has been shown to down regulate expres sion of Glut4, βadrenergic receptors and PParγ, which results in insulin resistance, hepatic steatosis and increased adiposity. 59 Finally, lower levels of adipocytesecreted hormones, such as leptin and adiponectin, may contribute to the metabolic abnormalities associated with hals and are discussed further below.
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Current treatment of lipodystrophy Given the heterogeneous nature of lipodystrophy, the treatment options are unsurprisingly diverse and have variable efficacy depending on the type of lipo dystrophy and individual presentation of the disorder. the treatment of lipodystrophy aims to ameliorate both the metabolic disturbances and pathological changes in adipose tissue distribution. an overview of current treatment strategies is provided herein, with a focus on the treatment of hals, the most prevalent form of lipodystrophy.
lifestyle modification

Diet and nutritional therapy
Dietary guidelines for lipodystrophy have not been established. however, given the increased risk of cardio vascular disease and diabetes mellitus, patients with lipodystrophy should adhere to the guidelines of the american heart association, which recommends that <30% of daily calories come from fat, 61 and the american Diabetes association, which recommends that carbo hydrate and monounsaturated fat should provide 60-70% of daily calories. 62 although limited data have been published regarding the mediterranean diet and other types of lipo dystrophy, some evidence suggests that the mediterranean dietwhich consists of plentiful intake of vegetables, fruits, whole grain cereals and olive oil; moderate intake of fish, dairy products and alcohol; and low intake of red meat, saturated fats, and sweets-may benefit indivi duals with hals.
63,64 a crosssectional study has shown that greater adherence to a mediterranean diet decreases cardiovascular risk factors in patients with hals, speci fically by improving insulin resistance and raising levels of hDl cholesterol.
64 supplementation with fiber, 65, 66 fish oil that contains high doses of omega3 fatty acids 65, 67 and vitamin e 68 may also benefit patients with hals. some evidence suggests that serum triglyceride levels and insulin resistance can be improved by sub stituting longchain fatty acids with mediumchain or n3 polyunsaturated fatty acids. 69 Exercise although very few studies have examined the effects of exercise on congenital lipodystrophies, exercise has been shown to benefit patients with hals. small clinical trials suggest that resistance training may be more important than aerobic exercise. a combination of aerobic and resistance training has been shown to improve cho lesterol levels, triglyceride levels and body composition, 70 whereas aerobic exercise alone has not been consistently shown to improve metabolic para meters or anthropo metric features. 65, 71, 72 resistance training alone increases total lean mass and decreases total, truncal and limb adipose tissue, reduces tri glyceride levels, increases hDl cholesterol levels and improves peripheral insulin sensi tivity. 72, 73 overall, increased physical activity of any kind is potentially beneficial for the prevention and improve ment of lipo dystrophy 74, 75 and augments pharmacologic therapy. 76 however, in lowweight patients who exhibit primarily lipoatrophy, exercise may exacerbate adipose tissue loss and is, therefore, not always recommended. 77 
Management of diabetes mellitus
Metformin metformin is an FDaapproved drug recommended for use in patients with type 2 diabetes mellitus, but not in those with lipodystrophy. however, many patients with lipodystrophy have concurrent diabetes mellitus and are thus on this medication. Data on the effects of metformin-which improves insulin sensitivity by decreasing hepatic gluconeogenesis and enhancing peripheral glucose utilization-on lipodystrophy are mainly from studies on patients with hals. an initial small, randomized controlled trial showed that treat ment with metformin significantly reduced insulin resistance, weight and diastolic blood pressure; a trend towards decreased visceral abdominal adipose tissue in patients with hals was also found. 78 these results were sustained during an openlabel extension of the trial. 79 a subsequent trial that compared metformin and rosiglitazone for the treatment of hals found that met formin improves insulin sensitivity to the same degree as rosiglitazone, but it also improves accumulation of vis ceral adipose tissue, fasting lipid profile and endothelial function, effects not seen in the rosiglitazone group. 80 metformin is safe and generally welltolerated; although gastrointestinal symptoms are common, they are mild and usually transient. however, not all subsequent studies have shown consistent improvements in insulin resistance, lipid profile or anthropometric features. 81, 82 Furthermore, metformin can worsen peripheral adipose tissue loss and should, therefore, be used with caution in patients with lipoatrophy. 83 Thiazolidinediones similar to metformin, thiazolidinediones, such as pio glita zone and rosiglitazone, are FDaapproved for use in patients with type 2 diabetes mellitus, but not speci fically for lipodystrophy. they bind and activate the nuclear transcription factor PParγ, which regulates adipo cyte differentiation, maintenance and survival and promotes production of adiponectin. 84 in case reports of fa milial partial lipodystrophy, treatment with thiazolidine diones has been more effective than with met formin. Pioglitazone improves insulin resistance, hyper insulinemia and hyper triglyceridemia, as well as reverses features of poly cystic ovary syndrome and nonalcoholic steatohepatitis, comor bidities that are resistant to treatment with metformin alone. [85] [86] [87] [88] rosiglitazone also improves insulin sensitivity and hyperglycemia 89, 90 but can worsen the lipid profile reviewS in patients with lipo dystrophy and associated type 2 diabetes mellitus. 91 Data on thiazolidinedione therapy and the restora tion of adipose tissue in lipoatrophic areas has been conflicting; it seems that thiazolidine diones do not improve lipo atrophy in patients with FPlD2, but pi oglitazone may be efficacious in patients with hals. 92, 93 Pioglitazone shows more promise than rosiglitazone for the treatment of hals. 93 overall, trials show that rosiglitazone improves insulin sensitivity and possi bly lipoatrophy 94, 95 but worsens the lipid profile, as it increases levels of total cholesterol, lDl cholesterol and triglycerides. [96] [97] [98] [99] rosiglitazone may promote a more atherogenic lipid profile 100 and has been proposed, but not proven beyond any doubt, to increase cardiovascular risk in patients with diabetes mellitus. thus, the FDa has further restricted its access to patients in the usa with uncontrolled diabetes mellitus, whereas the european medicines agency has suspended rosiglitazone while awaiting additional data. Furthermore, treatment with rosiglitazone may reduce the bioavailability of some antiretroviral medications, including nevirapine. 101 Given the inconsistent results with rosiglitazone, treat ment with pioglitazone has been suggested to be prefer able, especially in patients at high cardiovascular risk. 102 treatment with pioglitazone for 12 months improves blood pressure, lipid profile and insulin resistance in patients with hals. 103 in a randomized, placebocontrolled trial, pioglitazone improved atrophy of limb adipose tissue, although the clinical benefits were not perceived by the patients, and hDl cholesterol levels also increased. 104 additional trials with pioglitazone are needed.
in conclusion, thiazolidinediones, particularly rosig lita zone, have been linked to edema, cardiovascular dis ease 102, 105 and bone loss, 106 adverse effects that may limit their therapeutic value. specific PParγ modulators under development, such as int131, may have a comparable efficacy to thiazolidinediones but with a much improved adverse effect profile and are greatly anticipated. 107 Management of dyslipidemia the goals of dyslipidemia treatment in lipodystrophy should follow those of established guidelines for coronary artery disease, including achievement of levels of total cho lesterol <5.2 mmol/l, hDl cholesterol ≥1.6 mmol/l, lDl cholesterol <1.8 mmol/l and tri glycerides <1.7 mmol/l. lifestyle modification is a necessary first step. Given pos sible adverse effects of lipidlowering medications and drug-drug interactions, adjustment of the antiretroviral regimen before the start of these medications should be considered, especially in patients who have low titers of hiv in response to antiviral therapy and have no or little presumed antiretroviral resistance. 108 Statins statins are 3hydroxy3methylglutaryl coenzyme a reductase inhibitors and are the firstline agents for hyper cholesterolemia in the general population. they also have antiinflammatory and antithrombotic proper ties and enhance endothelial function to reduce cardiovascular morbidity and mortality. case reports of patients with generalized lipodystrophy suggest that statins are benefi cial, but perhaps insufficient as monotherapy, for hypertriglyceridemia. 19 most research on statins and lipo dystrophy has focused on hals. trials have shown that pravastatin and rosuvastatin decrease total and lDl cho lesterol levels 109, 110 and can increase subcutaneous adipose tissue in the extremities. 111 Furthermore, statins can improve endothelial function. 112, 113 this finding is par ticularly important in patients with hals, especially for those on protease inhibitors, as these individuals exhibit a higher rate of endothelial dysfunction compared with the general population. 114, 115 nevertheless, a caveat for the use of statins in patients with hals is that they interact with antiretroviral medications. Protease inhibitors can increase concentrations of simvastatin and atorvastatin to 30fold and threefold, respectively, and decrease con centrations of pravastatin by half.
116,117 the concentrations of haart medications seem not to be markedly altered by statins; 116, 118 however, statin therapy must be tailored to the haart regimen.
Fibrates if hypertriglyceridemia is the primary lipid abnormality, which is common among patients with hals (especially those on protease inhibitors), fibrates are an excellent option and have not been found to interact with haart medications. 119 Fenofibrate may be more efficacious than gemfibrozil; [119] [120] [121] however, direct comparisons of these drugs in patients with hals are lacking. Both agents are welltolerated, although rhabdomyolysis and renal failure have been reported with fibrate use. 122 Nicotinic acid extendedrelease nicotinic acid is also effective for hypertriglyceridemia; however, it may exacerbate insulin resistance in patients with hiv who are already prone to insulin resistance. 123, 124 acipimox, a nicotinic acid analog, may be a better option in these patients, as it has been found to decrease triglyceride levels and improve insulin sensitivity in hals. 125 Ezetimibe ezetimibe inhibits cholesterol absorption and can be an option for patients who are intolerant to statins. in hiv infected patients, ezetimibe has been found to be as effec tive as statins for the reduction of lDl cholesterol levels, but it does not improve endothelial function. 126 Previous trials that failed to demonstrate improved cardiovascular outcomes in patients without lipodystrophy have limited enthusiasm for this class of medications.
Management of HAlS
Modification of HAART with initiation of haart, patients should be carefully evaluated for cardiovascular risk factors based on guide lines of the national cholesterol education Program adult treatment Panel iii. if the patient is at high risk, the drug with the least metabolic complications should be selected. specifically, protease inhibitors should be reviewS avoided as they have been associated with myocardial infarction. 127 in patients with dyslipidemia, a switch from a protease inhibitor to nevirapine or abacavir can improve total cholesterol and triglyceride levels and may be preferable to the start of a lipidlowering drug. 127 haart medications can also be changed if lipo dystrophy develops, but the reversal of these adverse effects is usually slow. in lipohypertrophy, no specific antiretroviral drug has been implicated, whereas in patients with lipoatrophy, a regimen with the thymidine analogs stavudine and zidovudine should be avoided. 128 nrtis may inhibit mitochondrial γDna polymerase, as well as cause other mitochondrial defects, 42 thereby con tributing to lipoatrophy.
2,42 coadministration of uridine with pyrimidines, including zalcitabine, stavudine, zido vudine and lamivudine, can improve lipoatrophy by reversing mitochondrial toxicity and lactic acidosis. 2, 129 however, the evidence is conflicting, as a subsequent ran domized study found that, although uridine supplemen tation improved mitochondrial Dna levels, loss of limb adipose tissue was not affected. 130 uridine supplemen tation also negatively affected levels of inflammatory markers and mitochondrial Dna in adipocytes. 130 GH and GHRH analogs although neither growth hormone (Gh) nor Ghreleasing hormone (Ghrh) analogs are FDaapproved for the treatment of hals at this time, Gh replacement is a promising treatment in this patient population, as indivi duals with hals tend to be Ghdeficient. 131 initial trials used high doses of recombinant human Gh (rhGh), up to 6 mg per day, and showed marked improvements in truncal obesity (up to 40% reduction) and mild improve ments in limb atrophy, as well as improvements in the lipid profile. [132] [133] [134] however, adverse effects included peripheral edema, myalgia, arthalgia, dysthesia, glucose intolerance and diabetes mellitus; most of these comor bidities were transient and reversible. 132, [134] [135] [136] [137] another concern exists over the increased risk of cancer with longterm Gh therapy, 136 especially as the benefits of Gh treatment are generally not sustained once therapy is discontinued. 136 nevertheless, sustained improvements in facial lipo atrophy for up to 6 months after therapy discontinuation have been reported. 138 although high doses (4-6 mg daily) result in a greater reduction of visceral adipose tissue, 136 low doses (<20 mg per week) have been found to be relatively efficacious in reducing visceral adipose tissue and improving facial lipoatrophy and the lipid profile. 134, 138, 139 low doses seem to show less adverse effects; however, glucose intolerance remains a concern. [134] [135] [136] Ghrh analogs are also efficacious and can avoid the adverse effect of glucose intolerance. sermorelin, a Ghrh analog, has been shown to increase lean body mass, decrease truncal adipose tissue and abdominal vis ceral adipose tissue without affecting glycemic in dices. 140 similarly, tesamorelin, another Ghrh analog, has been shown to improve anthropometric features as well as tri glyceride levels and the ratio of cholesterol to hDl cho lesterol, again without affecting glycemic indices. [140] [141] [142] the overall number of patients with adverse events did not differ between treatment and placebo groups.
142 a subsequent study of longer duration confirmed improve ments in anthropometric features with tesamorelin therapy, in particular decreased visceral adipose tissue. 143 however, similar to Gh, Ghrh does not seem to confer any metabolic or anthropometric benefits upon discon tinuation, although improvements in selfassessed body image have been reported. 142, 143 trials involving Gh and Ghrh analogs are ongoing and will further elucidate the potential of Ghbased therapies.
Management of cosmetic appearance
Given the psychosocial implications of lipodystrophy, surgery might be an attractive option for some patients. Facial fillers can be used for facial lipoatrophy and have been shown to improve quality of life, as well as depres sion and anxiety symptoms. 144 For the dorso cervical adipose tissue pad or other areas of subcutaneous adipose tissue accumulation, liposuction is successful, but recurrence remains a potential problem. 144 Adipokines in lipodystrophy alterations in adipose tissue distribution affect levels of adipokines, including adiponectin and leptin. these hormones seem to have a fundamental role in the metabolic abnormalities seen in lipodystrophy, 145 and replacement of adipokines may have considerable therapeutic value for patients deficient in adipokines, primarily those with generalized lipodystrophies and a subset of patients with hals.
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Adiponectin adiponectin, a 244amino acid protein, is an endo genous insulin sensitizer. it reduces gluconeogenesis in the liver, primarily via the stimulation of adipo nectin receptor 2 (aDiPor2) and activation of amPK phosphorylation. adiponectin also increases fatty acid oxidation in muscle via aDiPor1. additionally, aDiPor1 stimulation in the hypothalamus might exert effects on insulin and leptin signaling, which promote increased insulin sensi tivity and reduced food intake. 146 adiponectin levels are low in a subset of individuals with lipodystrophy, including many patients with cGl1 and hals.
10,147-149 hypoadiponectinemia is associ ated with insulin resistance, hypertriglyceridemia and adipose tissue re distribution in hivinfected patients on antiretroviral medications. 60, 96, 150 in mouse studies, adiponectin administration improves insulin sensitivity, dyslipidemia and weight. 151 adiponectin replacement has also been shown to ame liorate ritonavirinduced hypertriglyceridemia and elevated FFa levels in mice. 152 although adiponectin or leptin alone improves insulin resistance in mouse models of lipodystrophy, 153, 154 the combined administration of both hormones fully normalizes insulin sensitivity. 155 no synthetic form of adiponectin is yet available for treat ment in humans; nevertheless, animal studies, 151, 152, 155 as well as studies on medications that increase endogenous levels of adiponectin (that is, pioglitazone or int131) have highlighted this adipokine's therapeutic potential. Further research is needed to elucidate the efficacy of these medications in humans and determine how long the benefits of treatment are sustained both during treatment and upon discontinuation. nevertheless, an adiponectin analog or adiponectin receptor modula tor could be an invaluable addition to our therapeutic ar mamentarium for lipodystrophy. leptin a substantial subset of patients with lipodystrophy exhibit low leptin levels, including most patients with generalized lipodystrophy and up to 40-80% of patients with hals.
3,10 leptin is primarily produced by white adipose tissue and correlates positively with body adiposity, as it reflects the amount of energy stores. 156 acting via a complex neural circuit, leptin promotes satiety, leading to decreased food intake. 157 leptin also acts peripherally to decrease gluconeogenesis in the liver and adipose tissue and to increase glucose utiliza tion in skeletal muscle by activating signaling pathways which overlap with, but are not identical to, those of insulin. 158 Finally, leptin protects peripheral tissues from lipo toxicity by stimulating fatty acid oxidation, as it has been shown to reduce intrahepatic and intra myocellular lipid accumulation. 159 Animal studies animal research suggests that leptin plays an integral part in certain forms of lipodystrophy. low leptin levels are a common finding in mouse models of general ized lipo dystrophy, including Pparg knockout mice, 160 Cav1 null mice, 161 Agpat2 null mice, 162 aP2Dta mice, 163 aZiP/F1 mice 164 and aP2nsrebp1c mice. 153 administration of leptin favorably affects the meta bolic profile in several of these mouse models. 153, 154, 165, 166 specifically, systemic leptin infusion was associated with improvements in insulin resistance and a reduction in hepatic steatosis in aP2nsrebp1c transgenic mice, which express a dominantly active form of Srebp1c in adipose tissue and exhibit markedly reduced white adipose tissue depots, as well as metabolic abnormalities. 153 Further more, chronic restriction of food intake alone did not account for all the metabolic benefits observed, which suggests that leptin improves the metabolic profile of lipodystrophic mice by other mechanisms. 153 similarly, lowdose intracerebroventricular leptin infusion ameliorates insulin resistance and hepatic steatosis in aP2nsrebp1c mice, an effect mediated by repression of stearoylcoa desaturase1 (scd1) acti vity in lipo dystrophic murine livers. 154 Dose-response experiments showed that peripheral subcutaneous leptin administration improved both hyperglycemia and hyper insulinemia at a lower dose than was required to improve hepatic steato sis. 154 this lower dose was found to normalize insulinstimulated phosphorylation of the insulin receptor and irs2, as well as activation of irs2 associated Pi3k and akt in the liver. 154 leptin has also been shown to improve metabolic parameters in lipoatrophic aZiP/F1 mice, which express a protein that inactivates (via hetero dimerization) several transcription factors belonging to the basic region-leucine zipper family, in a study that crossed these mice with lean mice which over express leptin. 165 Furthermore, surgical transplantation of normal adipose tissue into aZiP/F1 mice improves insulin resistance and other metabolic factors, 166 whereas adipose tissue from leptindeficient ob/ob mice does not. 167 similarly, PParγdeficient heterozygous mice (PParγ +/-) treated with leptin exhibit partial improvements in insulin resistance; when these mice are co administered physio logical doses of leptin and ad iponectin, insulin resistance is completely normalized. 155 Leptin replacement in humans in humans, recombinant human leptin (metreleptin) has been extensively studied in the context of openlabel, clini cal trials. [168] [169] [170] [171] Physiological replacement doses of leptin (0.04-0.08 mg/kg daily) have provided tangible benefits to patients with severe leptin deficiency from congenital and nonhivrelated acquired generalized lipodystrophy. these benefits include improvements in insulin sensitivity, glucose tolerance, levels of fasting glucose and hba 1c , hypertriglyceridemia and trans aminitis, thus lessening the need for insulin or oral hypo glycemic agents. [172] [173] [174] [175] [176] [177] [178] [179] leptin replacement also favorably changes body composition (weight loss with decreased adipose tissue and lean mass), 178, 180 an effect which is partially owing to increased satiety. 181 Furthermore, patients with partial lipodystrophy, including those with syndromes associated with LMNA and PPARγ gene mutations, also gain metabolic benefits from leptin treatment. 173, 182, 183 although all studies in individuals with cGl have been nonrandomized, openlabel trials, metreleptin is currently available for patients with lipo dystrophy refractory to other treatments through an FDaapproved expanded access program. 168, 177 metreleptin provides benefits beyond improvements in metabolic parameters. metreleptin reduces protein uria and ameliorates glomerular injury associated with general ized lipodystrophy 184 and normalizes men strual abnormalities, estradiol levels and the luteinizing hormone response to gonadotropinreleasing hormone in young women with lipodystrophy and polycystic ovary syndrome. 178, 185 leptin replacement can also have beneficial immunomodulatory effects in hypoleptinemic patients with severe lipodystrophy. 186 although open label trials have demonstrated benefits of metreleptin in these forms of lipodystrophy, larger, randomized, placebocontrolled trials are needed to conclusively prove its efficacy and safety, particularly as several adverse effects have been noted, including proteinuric nephro pathy 184 and tcell lymphomas 177, 187 in a small number of indivi duals. nevertheless, it seems as though the benefits of leptin replacement are sustained for as long as treat ment con tinues (that is, refractory changes in metabolic para meters and/or body composition have been largely attributed to treatment nonadherence), as patients fol lowed for up to 8 years of uninterrupted metreleptin treatment have continued to benefit from therapy. 173 to date, metreleptin treatment ceased to be efficacious only reviewS in a small number of patients with cGl2, potentially owing to the development of leptin resistance. 188 in a randomized, placebocontrolled, doubleblinded, crossover study evaluating the use of metreleptin, administra tion of physiological replacement doses to hypoleptinemic men with hals was found to improve fasting insulin levels, insulin resistance, hDl cho lesterol and truncal obesity. 189 an independent trial of longer duration confirmed these results. 190 the improvements in visceral adiposity and lipid levels exhibited by patients with hals treated with metreleptin 189, 190 were compar able to those reported with other therapeutics, includ ing metformin and thiazolidinediones. 78, 79, 97, 125, [132] [133] [134] Furthermore, the improvements in insulin resistance reported in patients with hals treated with metre leptin 189, 190 provide an advantage over Gh replacement therapy, given the associ ation of Gh treatment with glucose intolerance. 135, 136 in both trials, metreleptin was welltolerated, and no adverse effects were observed with treatment up to 36 months. 174 the extent to which patients with comparatively high endogenous leptin levels would benefit from metreleptin therapy remains to be determined, but the improvements are expected to be less striking than those observed in patients with severe leptin deficiency. 191 leptin's beneficial effects are mediated independently of the Gh and insulinlike growth factor 1 (iGF1) system. 192 as the Gh-iGF1 system may also have a role in hals, a combination therapy with leptin and Gh or Ghrh analogs could potentially have additive metabolic benefits without adversely affecting glucose intoler ance, 191 but this hypothesis remains to be addressed. even more importantly, whether the co administration of metreleptin and adiponectin has synergistic effects on the normalization of insulin resistance in humans with lipodystrophy, as has been reported in mice, is still not known. 155 Pilot studies on the combined administra tion of pioglitazone and metreleptin are underway, and preliminary data indicate that this combination further improves gl ycemic control. 193 Conclusions current advancements in the treatment of lipodystrophy are timely. not only new viable means to treat a severe disorder but also the role of adipose tissue are being un covered, and insights into areas of growing concern, such as insulin signaling and fatty acid metabolism, have been gained, which will hopefully provide the basis for rational drug design and use. more work is needed to further explore ways to ameliorate the degree of adipose tissue loss, as well as pathological adipose tissue accumula tion, in patients with lipodystrophy and to prevent and treat the concomitant metabolic disturbances and the associated longterm morbidity and mortality. these objectives are particularly relevant for the population with hiv. with the advent of haart, an increase in the life expectancy of hivpositive individuals has been observed 194 owing to the efficacy of current treatments to suppress viral load; however, the success of medications for hiv is accompanied by adverse drug effects and toxic ity. although the ultimate goal is to prevent (via micro bicides, vaccines and/or antiviral prophylaxis) or even cure hiv infection, more tangible future aims will probably be to manage adverse effects (including lipodystrophy and insulin resistance) and to better understand the impact of longterm use of hiv medications, given the growing number of elderly hivpositive patients. 195 Furthermore, the increased number of patients with hiv, as a result of longer survival, could lead to increasing morbidity and mortality in the future. this phenomenon, in turn, creates an urgent unmet need and provides pressure for the pharma ceutical industry to develop newer and safer medications than currently available that are hopefully devoid of adverse effects such as lipodystrophy.
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